TABLE 3 | Monoclonal antibodies currently FDA approved in oncology and their mechanisms of action

From the following article:

Antibody therapy of cancer

Andrew M. Scott, Jedd D. Wolchok & Lloyd J. Old

Nature Reviews Cancer 12, 278-287 (April 2012)

doi:10.1038/nrc3236

AntibodyTargetFDA-approved indicationApproval in Europe*Mechanisms of action
Naked antibodies: solid malignancies
Trastuzumab (Herceptin; Genentech): humanized IgG1ERBB2ERBB2-positive breast cancer, as a single agent or in combination with chemotherapy for adjuvant or palliative treatmentSimilarInhibition of ERBB2 signalling and ADCC
  ERBB2-positive gastric or gastro-oesophageal junction carcinoma as first-line treatment in combination with cisplatin and capecitabine or 5-fluorouracil  
Bevacizumab (Avastin; Genentech/Roche): humanized IgG1VEGFFor first-line and second-line treatment of metastatic colon cancer, in conjunction with 5-fluorouracil-based chemotherapy; for first-line treatment of advanced NSCLC, in combination with carboplatin and paclitaxel, in patients who have not yet received chemotherapy; as a single agent in adult patients with glioblastoma whose tumour has progressed after initial treatment; and in conjunction with IFN╬▒ to treat metastatic kidney cancerSimilarInhibition of VEGF signalling
Cetuximab (Erbitux; Bristol-Myers Squibb): chimeric human–murine IgG1EGFRIn combination with radiation therapy for the initial treatment of locally or regionally advanced SCCHN; as a single agent for patients with SCCHN for whom prior platinum-based therapy has failed; and palliative treatment of pretreated metastatic EGFR-positive colorectal cancerSimilarInhibition of EGFR signalling and ADCC
Panitumumab (Vectibix; Amgen): human IgG2EGFRAs a single agent for the treatment of pretreated EGFR-expressing, metastatic colorectal carcinomaSimilarInhibition of EGFR signalling
Ipilimumab (Yervoy; Bristol-Myers Squibb): IgG1CTLA4For the treatment of unresectable or metastatic melanomaSimilarInhibition of CTLA4 signalling
Naked antibodies: haematological malignancies
Rituximab (Mabthera; Roche): chimeric human–murine IgG1CD20For the treatment of CD20-positive B cell NHL and CLL, and for maintenance therapy for untreated follicular CD20-positive NHLSimilarADCC, direct induction of apoptosis and CDC
Alemtuzumab (Campath; Genzyme): humanized IgG1CD52As a single agent for the treatment of B cell chronic lymphocytic leukaemiaSimilarDirect induction of apoptosis and CDC
Ofatumumab (Arzerra; Genmab): human IgG1CD20Treatment of patients with CLL refractory to fludarabine and alemtuzumabSimilarADCC and CDC
Conjugated antibodies: haematological malignancies
Gemtuzumab ozogamicin (Mylotarg; Wyeth): humanized IgG4CD33For the treatment of patients with CD33-positive acute myeloid leukaemia in first relapse who are 60 years of age or older and who are not considered candidates for other cytotoxic chemotherapy; withdrawn from use in June 2010Not approved in the European UnionDelivery of toxic payload, calicheamicin toxin
Brentuximab vedotin (Adcetris; Seattle Genetics): chimeric IgG1CD30For the treatment of relapsed or refractory Hodgkin's lymphoma and systemic anaplastic lymphomaNot approved in the European UnionDelivery of toxic payload, auristatin toxin
90Y-labelled ibritumomab tiuxetan (Zevalin; IDEC Pharmaceuticals): murine IgG1CD20Treatment of relapsed or refractory, low-grade or follicular B cell NHLSimilarDelivery of the radioisotope 90Y
  Previously untreated follicular NHL in patients who achieve a partial or complete response to first-line chemotherapy  
131I-labelled tositumomab (Bexxar; GlaxoSmithKline): murine IgG2CD20Treatment of patients with CD20 antigen-expressing relapsed or refractory, low-grade, follicular or transformed NHLGranted orphan status drug in 2003 in the European UnionDelivery of the radioisotope 131I, ADCC and direct induction of apoptosis
ADCC, antibody-dependent cellular cytotoxicity; CDC, complement-dependent cytotoxicity; CLL, chronic lymphocytic leukaemia; CTLA4, cytotoxic T lymphocyte-associated antigen 4; EGFR, epidermal growth factor receptor; FDA, US Food and Drug Administration; IgG, immunoglobulin G; INFa; interferon-a; NHL, non-Hodgkin's lymphoma; NSCLC, non-small-cell lung cancer; SCCHN, squamous cell carcinoma of the head and neck; VEGF, vascular endothelial growth factor.
*Based on information from the European Medicines Agency. Not recommended for patients with colorectal cancer whose tumours express mutated KRAS.

Download file

If the slide opens in your browser, select "File > Save As" to save it.